Novartis, a global pharmaceutical company, have claimed that their new clinical data proves the efficacy of diabetes drug Galvus. The company are providing a new safety profile to regulators.
New data from clinical trials will be published in Diabetes, Obesity and Metabolism. The data apparently confirms the efficiency of the new oral medicine as a leading oral treatment for type 2 diabetes.
Beyond this, the company have provided a safety update to European regulators, making a further case that Galvus, when administered in the correct doses, is safe. The study data also states that Glavus is efficient alongside diabetes drug metformin. The drug was apparently well-tolerated and didn’t cause weight gain.
Novartis are in discussion with the US Food and Drug Administration on whether Galvus can be approved for US use.

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…

Conversation about doctors’ appointments occurring virtually rumbles on

More than half of GP appointments are still being delivered remotely in…

Type 2 diabetes found to be a ‘significant risk factor’ among stroke victims

More evidence has been published which supports that diabetes is a “significant…